Revolutionizing market assessment, patient discovery, healthcare provider intelligence, key opinion leader identification, treatment journey mapping, study recruitment, adherence monitoring and personalised brand engagement.
Who is my target patient population? What is their diagnostic journey? How large is the market for my candidate therapy?
Who are my ideal patients to recruit for study? Where do these patient clusters exist? Which HCPs and KOL/KOI are most engaged?
How do we accelerate peak revenue, focus on the highest value patient targets and maximize personal promotion efforts with HCPs?
Powered by machine learning, artificial intelligence and evolutionary computation in conjunction with a granular longitudinal data pool that consists of 300 million unique de-identified patients with a 10 year look-back and refreshed weekly.
Customers that have partnered with IPM.ai to educate the life sciences industry on accelerating the successful development and commercialization of life-saving therapies for emerging and specialty markets with under-defined patient populations.
Our unparalleled ability to demonstrate empirical results is rooted in our unique combination of a granular RWD universe, decades of in-house consulting, technology and domain expertise, as well as a modern machine learning and artificial intelligence infrastructure.
Whether seeking patients yet to be diagnosed with a rare or specialty disease, ready to progress to your 2nd or 3rd line therapy or at risk of non-adherence, our solutions focus on developing the business rules to isolate the ideal patient population, leveraging ML/AI to predict the lookalike audience at scale and associate physicians via several different attribution techniques.
We examine the pathways and critical moments across the continuum of care to address various questions related to both the patient experience (e.g., demographics, co-morbidities, prior treatment, diagnostic testing, signs and symptoms) and the provider dynamics (e.g., place of service, specialty and payer makeup) to provide a high-definition view of leverage points.
While the industry has historically used field intelligence, primary research and secondary data to understand healthcare providers, we place the patient at the center of all analysis and draw on years of granular-level patient-provider interaction data to effectively map treating physicians, referral patterns and key opinion leaders for disease states.
Simply put, we really value our partnership with IPM.ai
Shortening the Rare Disease Diagnostic Odyssey is filled with proven methodologies, use cases and success stories on how pharmaceutical companies can identify, engage and educate ideal patients who could benefit from innovative therapies and modalities of care.